Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis

A. Ng; P. F. Ravetto; G. M. Taylor; R. F. Wynn; O. B. Eden

Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis

A. Ng, P. F. Ravetto, G. M. Taylor, R. F. Wynn, O. B. Eden

Research output: Contribution to journal › Article › peer-review

Abstract

Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is characterised by the presence of mixed lineage leukaemia (MLL) rearrangement. By molecular tracking, we were able to show that MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with haemophagocytic lymphohistiocytosis. This is the first report on the sequential detection of the two biomarkers in treatment-related leukaemogenesis. © 2004 Cancer Research UK.

Original language	English
Pages (from-to)	1990-1992
Number of pages	2
Journal	British Journal of Cancer
Volume	91
Issue number	12
Publication status	Published - 13 Dec 2004

Keywords

HLH
MLL cleavage and rearrangement
Treatment-related leukaemia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a09dcef5d91a49758829f13a713ac324,

title = "Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis",

abstract = "Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is characterised by the presence of mixed lineage leukaemia (MLL) rearrangement. By molecular tracking, we were able to show that MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with haemophagocytic lymphohistiocytosis. This is the first report on the sequential detection of the two biomarkers in treatment-related leukaemogenesis. {\textcopyright} 2004 Cancer Research UK.",

keywords = "HLH, MLL cleavage and rearrangement, Treatment-related leukaemia",

author = "A. Ng and Ravetto, {P. F.} and Taylor, {G. M.} and Wynn, {R. F.} and Eden, {O. B.}",

year = "2004",

month = dec,

day = "13",

language = "English",

volume = "91",

pages = "1990--1992",

journal = "BJC",

issn = "0007-0920",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis

AU - Ng, A.

AU - Ravetto, P. F.

AU - Taylor, G. M.

AU - Wynn, R. F.

AU - Eden, O. B.

PY - 2004/12/13

Y1 - 2004/12/13

N2 - Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is characterised by the presence of mixed lineage leukaemia (MLL) rearrangement. By molecular tracking, we were able to show that MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with haemophagocytic lymphohistiocytosis. This is the first report on the sequential detection of the two biomarkers in treatment-related leukaemogenesis. © 2004 Cancer Research UK.

AB - Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is characterised by the presence of mixed lineage leukaemia (MLL) rearrangement. By molecular tracking, we were able to show that MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with haemophagocytic lymphohistiocytosis. This is the first report on the sequential detection of the two biomarkers in treatment-related leukaemogenesis. © 2004 Cancer Research UK.

KW - HLH

KW - MLL cleavage and rearrangement

KW - Treatment-related leukaemia

M3 - Article

VL - 91

SP - 1990

EP - 1992

JO - BJC

JF - BJC

SN - 0007-0920

IS - 12

ER -

Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis

Abstract

Keywords

UN SDGs

Fingerprint

Cite this